Literature DB >> 23356674

A nationwide seroepidemiology of hepatitis C virus infection in South Korea.

Do Young Kim1, In Hee Kim, Sook-Hyang Jeong, Yong Kyun Cho, Joon Hyoek Lee, Young-Joo Jin, Don Lee, Dong Jin Suh, Kwang-Hyub Han, Neung Hwa Park, Ha Yan Kang, Young Kul Jung, Young Seok Kim, Kyung-Ah Kim, Youn Jae Lee, Byung Seok Lee, Hyung Joon Yim, Heon Ju Lee, Soon Koo Baik, Won Young Tak, Sun Jae Lee, Woo Jin Chung, Sung-Kyu Choi, Eun-Young Cho, Jeong Heo, Dong Joon Kim, Byung-Cheol Song, Man Woo Kim, Jun Lee, Hee Bok Chae, Dae Hee Choi, Hwa Young Choi, Moran Ki.   

Abstract

BACKGROUND & AIMS: The aim of this study was to reveal nationwide seroprevalence of HCV infection in South Korea by a large-scale survey.
METHODS: From January to December 2009, a total of 291 314 adults underwent health check-up in 29 centres nationwide. The data concerning anti-HCV antibody and biochemical tests were obtained from all participants. Among subjects with positive anti-HCV, such data as HCV RNA, genotypes and treatment detail were additionally analysed.
RESULTS: Using an estimated 2009 population of Korea, the age, sex and area-adjusted anti-HCV positive rate was 0.78%. Anti-HCV prevalence in female patients (0.83%) was higher than that in male patients (0.75%). Gradual increase in anti-HCV positivity was observed, from 0.34% in those aged 20-29 years to 2.31% in those >70 years. The age- and sex-adjusted anti-HCV prevalence varied in different areas, being higher in Busan and Jeonnam (1.53-2.07%), mid-level in Seoul and surrounding districts (0.50-0.61%) and lower in Jeju (0.23%). The comparative analysis of laboratory variables between anti-HCV (+) and anti-HCV (-) group revealed significantly higher levels of alanine aminotransferase and lower levels of serum lipids in anti-HCV (+) group. Among 1 718 anti-HCV positive subjects, serum HCV RNA was measured only in 478 people, of whom 268 (56.1%) patients had detectable HCV RNA in serum. Among 50 patients for whom assessment of response to antiviral therapy was feasible, overall sustained virological response was achieved in 84% of patients.
CONCLUSION: The prevalence of HCV infection is low in South Korea. Studies to analyse risk factors are warranted to reduce HCV infection.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23356674     DOI: 10.1111/liv.12108

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  50 in total

1.  Retrospective analysis on the diagnostic performances and signal-to-cut-off ratios of the Elecsys Anti-HCV II assay.

Authors:  Banseok Kim; Hyo Jun Ahn; Min Hyuk Choi; Yongjung Park
Journal:  J Clin Lab Anal       Date:  2017-02-10       Impact factor: 2.352

Review 2.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

Authors:  Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-12-15

Review 3.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

4.  Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.

Authors:  Chansoo Moon; Kyu Sik Jung; Do Young Kim; Oidov Baatarkhuu; Jun Yong Park; Beom Kyung Kim; Seung Up Kim; Sang Hoon Ahn; Kwang-Hyub Han
Journal:  Dig Dis Sci       Date:  2014-09-19       Impact factor: 3.199

Review 5.  A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan.

Authors:  Heather Bennett; Nathalie Waser; Karissa Johnston; Jia-Horng Kao; Young-Suk Lim; Zhong-Ping Duan; Youn-Jae Lee; Lai Wei; Chien-Jen Chen; William Sievert; Yong Yuan; Hong Li
Journal:  Hepatol Int       Date:  2015-06-13       Impact factor: 6.047

6.  The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015.

Authors:  Eun Sun Jang; Moran Ki; Hwa Young Choi; Kyung-Ah Kim; Sook-Hyang Jeong
Journal:  Hepatol Int       Date:  2019-08-20       Impact factor: 6.047

7.  A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.

Authors:  Young-Suk Lim; Sang Hoon Ahn; Kwan Sik Lee; Seung Woon Paik; Youn-Jae Lee; Sook-Hyang Jeong; Ju-Hyun Kim; Seung Kew Yoon; Hyung Joon Yim; Won Young Tak; Sang-Young Han; Jenny C Yang; Hongmei Mo; Kimberly L Garrison; Bing Gao; Steven J Knox; Phillip S Pang; Yoon Jun Kim; Kwan-Soo Byun; Young Seok Kim; Jeong Heo; Kwang-Hyub Han
Journal:  Hepatol Int       Date:  2016-05-20       Impact factor: 6.047

8.  Hepatitis C virus seroprevalence in the general female population from 8 countries.

Authors:  Paloma Quesada; Denise Whitby; Yolanda Benavente; Wendell Miley; Nazzarena Labo; Saibua Chichareon; Nguyen Trong; Hai-Rim Shin; Pham Thi Hoang Anh; Jaiyeola Thomas; Elena Matos; Rolando Herrero; Nubia Muñoz; Monica Molano; Silvia Franceschi; Silvia de Sanjosé
Journal:  J Clin Virol       Date:  2015-05-12       Impact factor: 3.168

9.  The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2.

Authors:  Sung Yong Han; Hyun Young Woo; Jeong Heo; Sang Gyu Park; Sung Ik Pyeon; Young Joo Park; Dong Uk Kim; Gwang Ha Kim; Hyung Hoi Kim; Geun Am Song; Mong Cho
Journal:  Korean J Intern Med       Date:  2019-03-19       Impact factor: 2.884

10.  Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study.

Authors:  Yeo Wool Kang; Yang Hyun Baek; Sung Wook Lee; Sung Jae Park; Jun Sik Yoon; Ki Tae Yoon; Youngmi Hong; Nae Yun Heo; Kwang Il Seo; Sang Soo Lee; Hyun Chin Cho; Jung Woo Shin
Journal:  J Korean Med Sci       Date:  2021-05-31       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.